Milk thistle-based dietary supplements have become increasingly popular. The extract from milk thistle (Silybum marianum) is often used for the treatment of liver diseases because of the presence of its active component, silymarin. However, the co-occurrence of toxic mycotoxins in these preparations is quite frequent as well. The objective of this study was to investigate the changes in composition of liver lipidome and other clinical characteristics of experimental mice fed by a high-fat methionine-choline deficient diet inducing non-alcoholic fatty liver disease. The mice were exposed to (i) silymarin, (ii) mycotoxins (trichothecenes, enniatins, beauvericin, and altertoxins) and (iii) both silymarin and mycotoxins, and results were compared to the controls. The liver tissue extracts were analyzed by ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry. Using tools of univariate and multivariate statistical analysis, we were able to identify 48 lipid species from the classes of diacylglycerols, triacylglycerols, free fatty acids, fatty acid esters of hydroxy fatty acids and phospholipids clearly reflecting the dysregulation of lipid metabolism upon exposure to mycotoxin and/or silymarin.

4th Department of Internal Medicine General University Hospital and 1st Faculty of Medicine Charles University 128 00 Prague Czech Republic

Department of Food Chemistry and Analysis University of Chemistry and Technology 166 28 Prague Czech Republic

Institute for Clinical and Experimental Medicine 140 21 Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital and 1st Faculty of Medicine Charles University 128 08 Prague Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences 142 20 Prague Czech Republic

Zobrazit více v PubMed

Fenclova M., Novakova A., Viktorova J., Jonatova P., Dzuman Z., Ruml T., Kren V., Hajslova J., Vitek L., Stranska-Zachariasova M. Poor Chemical and Microbiological Quality of the Commercial Milk Thistle-Based Dietary Supplements May Account for Their Reported Unsatisfactory and Non-Reproducible Clinical Outcomes. Sci. Rep. 2019;9:11118. doi: 10.1038/s41598-019-47250-0. PubMed DOI PMC

Peraica M., Radić B., Lucić A., Pavlović M. Toxic Effects of Mycotoxins in Humans. Bull. World Health Organ. 1999;77:754–766. PubMed PMC

Ahmed Adam M.A., Tabana Y.M., Musa K.B., Sandai D.A. Effects of Different Mycotoxins on Humans, Cell Genome and Their Involvement in Cancer (Review) Oncol. Rep. 2017;37:1321–1336. doi: 10.3892/or.2017.5424. PubMed DOI

Prosperini A., Berrada H., Ruiz M.J., Caloni F., Coccini T., Spicer L.J., Perego M.C., Lafranconi A. A Review of the Mycotoxin Enniatin B. Front. Public Health. 2017;5:304. doi: 10.3389/fpubh.2017.00304. PubMed DOI PMC

Tralamazza S.M., Piacentini K.C., Iwase C.H.T., Rocha L. de O. Toxigenic Alternaria Species: Impact in Cereals Worldwide. Curr. Opin. Food Sci. 2018;23:57–63. doi: 10.1016/j.cofs.2018.05.002. DOI

Marín S., Cano-Sancho G., Sanchis V., Ramos A.J. The Role of Mycotoxins in the Human Exposome: Application of Mycotoxin Biomarkers in Exposome-Health Studies. Food Chem. Toxicol. 2018;121:504–518. doi: 10.1016/j.fct.2018.09.039. PubMed DOI

Belser-Ehrlich S., Harper A., Hussey J., Hallock R. Human and Cattle Ergotism since 1900: Symptoms, Outbreaks, and Regulations. Toxicol. Ind. Health. 2013;29:307–316. doi: 10.1177/0748233711432570. PubMed DOI

Krishnamachari K.A., Bhat R.V., Nagarajan V., Tilak T.B. Hepatitis Due to Aflatoxicosis. An Outbreak in Western India. Lancet. 1975;1:1061–1063. doi: 10.1016/S0140-6736(75)91829-2. PubMed DOI

Meggs W.J. Epidemics of Mold Poisoning Past and Present. Toxicol. Ind. Health. 2009;25:571–576. doi: 10.1177/0748233709348277. PubMed DOI

Marin S., Ramos A.J., Cano-Sancho G., Sanchis V. Mycotoxins: Occurrence, Toxicology, and Exposure Assessment. Food Chem. Toxicol. 2013;60:218–237. doi: 10.1016/j.fct.2013.07.047. PubMed DOI

Eshelli M., Qader M.M., Jambi E.J., Hursthouse A.S., Rateb M.E. Current Status and Future Opportunities of Omics Tools in Mycotoxin Research. Toxins. 2018;10:433. doi: 10.3390/toxins10110433. PubMed DOI PMC

Liu G., Yan T., Wang J., Huang Z., Chen X., Jia G., Wu C., Zhao H., Xue B., Xiao L., et al. Biological System Responses to Zearalenone Mycotoxin Exposure by Integrated Metabolomic Studies. J. Agric. Food Chem. 2013;61:11212–11221. doi: 10.1021/jf403401v. PubMed DOI

Ji J., Zhu P., Cui F., Pi F., Zhang Y., Li Y., Wang J., Sun X. The Antagonistic Effect of Mycotoxins Deoxynivalenol and Zearalenone on Metabolic Profiling in Serum and Liver of Mice. Toxins. 2017;9:28. doi: 10.3390/toxins9010028. PubMed DOI PMC

Ji J., Zhu P., Blaženović I., Cui F., Gholami M., Sun J., Habimana J., Zhang Y., Sun X. Explaining Combinatorial Effects of Mycotoxins Deoxynivalenol and Zearalenone in Mice with Urinary Metabolomic Profiling. Sci. Rep. 2018;8:3762. doi: 10.1038/s41598-018-21555-y. PubMed DOI PMC

Szabó A., Szabó-Fodor J., Fébel H., Mézes M., Balogh K., Bázár G., Kocsó D., Ali O., Kovács M. Individual and Combined Effects of Fumonisin B1, Deoxynivalenol and Zearalenone on the Hepatic and Renal Membrane Lipid Integrity of Rats. Toxins. 2017;10:4. doi: 10.3390/toxins10010004. PubMed DOI PMC

Smith M.-C., Hymery N., Troadec S., Pawtowski A., Coton E., Madec S. Hepatotoxicity of Fusariotoxins, Alone and in Combination, towards the HepaRG Human Hepatocyte Cell Line. Food Chem. Toxicol. 2017;109:439–451. doi: 10.1016/j.fct.2017.09.022. PubMed DOI

Grenier B., Oswald I. Mycotoxin Co-Contamination of Food and Feed: Meta-Analysis of Publications Describing Toxicological Interactions. World Mycotoxin J. 2011;4:285–313. doi: 10.3920/WMJ2011.1281. DOI

Alassane-Kpembi I., Kolf-Clauw M., Gauthier T., Abrami R., Abiola F.A., Oswald I.P., Puel O. New Insights into Mycotoxin Mixtures: The Toxicity of Low Doses of Type B Trichothecenes on Intestinal Epithelial Cells Is Synergistic. Toxicol. Appl. Pharmacol. 2013;272:191–198. doi: 10.1016/j.taap.2013.05.023. PubMed DOI

Veprikova Z., Zachariasova M., Dzuman Z., Zachariasova A., Fenclova M., Slavikova P., Vaclavikova M., Mastovska K., Hengst D., Hajslova J. Mycotoxins in Plant-Based Dietary Supplements: Hidden Health Risk for Consumers. J. Agric. Food Chem. 2015;63:6633–6643. doi: 10.1021/acs.jafc.5b02105. PubMed DOI

Chambers C.S., Holečková V., Petrásková L., Biedermann D., Valentová K., Buchta M., Křen V. The Silymarin Composition… and Why Does It Matter??? Food Res. Int. 2017;100:339–353. doi: 10.1016/j.foodres.2017.07.017. PubMed DOI

Khatoon A., Khan M.Z., Khan A., Saleemi M.K., Javed I. Amelioration of Ochratoxin A-Induced Immunotoxic Effects by Silymarin and Vitamin E in White Leghorn Cockerels. J. Immunotoxicol. 2013;10:25–31. doi: 10.3109/1547691X.2012.686533. PubMed DOI

Sozmen M., Devrim A.K., Tunca R., Bayezit M., Dag S., Essiz D. Protective Effects of Silymarin on Fumonisin B1-Induced Hepatotoxicity in Mice. J. Vet. Sci. 2014;15:51–60. doi: 10.4142/jvs.2014.15.1.51. PubMed DOI PMC

Naseer O., Khan J.A., Khan M.S., Omer M.O., Chishti G.A., Sohail M.L., Saleem M.U. Comparative Efficacy of Silymarin and Choline Chloride (Liver Tonics) in Preventing the Effects of Aflatoxin B1 in Bovine Calves. Pol. J. Vet. Sci. 2016;19 doi: 10.1515/pjvs-2016-0068. PubMed DOI

Khaleghipour B., Khosravinia H., Toghiyani M., Azarfar A. Efficacy of Silymarin-Nanohydrogle Complex in Attenuation of Aflatoxins Toxicity in Japanese Quails. Ital. J. Anim. Sci. 2020;19:351–359. doi: 10.1080/1828051X.2020.1743782. DOI

El-Sheshtawy S.M., El-Zoghby A.F., Shawky N.A., Samak D.H. Aflatoxicosis in Pekin Duckling and the Effects of Treatments with Lycopene and Silymarin. Vet. World. 2021;14:788–793. doi: 10.14202/vetworld.2021.788-793. PubMed DOI PMC

Egresi A., Süle K., Szentmihályi K., Blázovics A., Fehér E., Hagymási K., Fébel H. Impact of Milk Thistle (Silybum Marianum) on the Mycotoxin Caused Redox-Homeostasis Imbalance of Ducks Liver. Toxicon. 2020;187:181–187. doi: 10.1016/j.toxicon.2020.09.002. PubMed DOI

Raj J., Vasiljević M., Tassis P., Farkaš H., Männer K. Efficacy of a Multicomponent Mycotoxin Detoxifying Agent on Concurrent Exposure to Zearalenone and T-2 Mycotoxin in Weaned Pigs. Livest. Sci. 2020;242:104295. doi: 10.1016/j.livsci.2020.104295. DOI

Viktorova J., Stranska-Zachariasova M., Fenclova M., Vitek L., Hajslova J., Kren V., Ruml T. Complex Evaluation of Antioxidant Capacity of Milk Thistle Dietary Supplements. Antioxidants. 2019;8:317. doi: 10.3390/antiox8080317. PubMed DOI PMC

Šuk J., Jašprová J., Biedermann D., Petrásková L., Valentová K., Křen V., Muchová L., Vítek L. Isolated Silymarin Flavonoids Increase Systemic and Hepatic Bilirubin Concentrations and Lower Lipoperoxidation in Mice. Oxid. Med. Cell. Longev. 2019;2019:6026902. doi: 10.1155/2019/6026902. PubMed DOI PMC

Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.-C., Torbenson M.S., Unalp-Arida A., et al. Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701. PubMed DOI

Koelmel J.P., Kroeger N.M., Ulmer C.Z., Bowden J.A., Patterson R.E., Cochran J.A., Beecher C.W.W., Garrett T.J., Yost R.A. LipidMatch: An Automated Workflow for Rule-Based Lipid Identification Using Untargeted High-Resolution Tandem Mass Spectrometry Data. BMC Bioinform. 2017;18:331. doi: 10.1186/s12859-017-1744-3. PubMed DOI PMC

Svegliati-Baroni G., Pierantonelli I., Torquato P., Marinelli R., Ferreri C., Chatgilialoglu C., Bartolini D., Galli F. Lipidomic Biomarkers and Mechanisms of Lipotoxicity in Non-Alcoholic Fatty Liver Disease. Free Radic. Biol. Med. 2019;144:293–309. doi: 10.1016/j.freeradbiomed.2019.05.029. PubMed DOI

Smith T., Kawa K., Eckl V., Morton C., Stredney R. Herbal Supplement Sales in US Increase 7.7% in 2016 Consumer Preferences Shifing toward Ingredients with General Wellness Benefits, Driving Growth of Adaptogens and Digestive Health Products. HerbalGram. 2017;115:56–65.

Féher J., Lengyel G. Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer. Curr. Pharm. Biotechnol. 2012;13:210–217. doi: 10.2174/138920112798868818. PubMed DOI

Zhong S., Fan Y., Yan Q., Fan X., Wu B., Han Y., Zhang Y., Chen Y., Zhang H., Niu J. The Therapeutic Effect of Silymarin in the Treatment of Nonalcoholic Fatty Disease: A Meta-Analysis (PRISMA) of Randomized Control Trials. Medicine. 2017;96:e9061. doi: 10.1097/MD.0000000000009061. PubMed DOI PMC

Ferenci P., Scherzer T., Kerschner H., Rutter K., Beinhardt S., Hofer H., Schöniger–Hekele M., Holzmann H., Steindl–Munda P. Silibinin Is a Potent Antiviral Agent in Patients with Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy. Gastroenterology. 2008;135:1561–1567. doi: 10.1053/j.gastro.2008.07.072. PubMed DOI

Seeff L.B., Bonkovsky H.L., Navarro V.J., Wang G. Herbal Products and the Liver: A Review of Adverse Effects and Mechanisms. Gastroenterology. 2015;148:517–532. doi: 10.1053/j.gastro.2014.12.004. PubMed DOI

de Avelar C.R., Pereira E.M., de Farias Costa P.R., de Jesus R.P., de Oliveira L.P.M. Effect of Silymarin on Biochemical Indicators in Patients with Liver Disease: Systematic Review with Meta-Analysis. World J. Gastroenterol. 2017;23:5004–5017. doi: 10.3748/wjg.v23.i27.5004. PubMed DOI PMC

Fried M.W., Navarro V.J., Afdhal N., Belle S.H., Wahed A.S., Hawke R.L., Doo E., Meyers C.M., Reddy K.R. Silymarin in NASH and C Hepatitis (SyNCH) Study Group Effect of Silymarin (Milk Thistle) on Liver Disease in Patients with Chronic Hepatitis C Unsuccessfully Treated with Interferon Therapy: A Randomized Controlled Trial. JAMA. 2012;308:274–282. doi: 10.1001/jama.2012.8265. PubMed DOI PMC

Yang Z., Zhuang L., Lu Y., Xu Q., Chen X. Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed. Res. Int. 2014;2014:941085. doi: 10.1155/2014/941085. PubMed DOI PMC

Chen Y., Lopez S., Hayward D.G., Park H.Y., Wong J.W., Kim S.S., Wan J., Reddy R.M., Quinn D.J., Steiniger D. Determination of Multiresidue Pesticides in Botanical Dietary Supplements Using Gas Chromatography–Triple-Quadrupole Mass Spectrometry (GC-MS/MS) J. Agric. Food Chem. 2016;64:6125–6132. doi: 10.1021/acs.jafc.6b00746. PubMed DOI

Nardin T., Piasentier E., Barnaba C., Larcher R. Targeted and Untargeted Profiling of Alkaloids in Herbal Extracts Using Online Solid-Phase Extraction and High-Resolution Mass Spectrometry (Q-Orbitrap) J. Mass Spectrom. 2016;51:729–741. doi: 10.1002/jms.3838. PubMed DOI

Tournas V.H., Rivera Calo J., Sapp C. Fungal Profiles in Various Milk Thistle Botanicals from US Retail. Int. J. Food Microbiol. 2013;164:87–91. doi: 10.1016/j.ijfoodmicro.2013.03.026. PubMed DOI

Arroyo-Manzanares N., García-Campaña A.M., Gámiz-Gracia L. Multiclass Mycotoxin Analysis in Silybum Marianum by Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry Using a Procedure Based on QuEChERS and Dispersive Liquid-Liquid Microextraction. J. Chromatogr. A. 2013;1282:11–19. doi: 10.1016/j.chroma.2013.01.072. PubMed DOI

Tournas V.H., Sapp C., Trucksess M.W. Occurrence of Aflatoxins in Milk Thistle Herbal Supplements. Food Addit. Contam. Part A. 2012;29:994–999. doi: 10.1080/19440049.2012.664788. PubMed DOI

Gorden D.L., Myers D.S., Ivanova P.T., Fahy E., Maurya M.R., Gupta S., Min J., Spann N.J., McDonald J.G., Kelly S.L., et al. Biomarkers of NAFLD Progression: A Lipidomics Approach to an Epidemic1. J. Lipid Res. 2015;56:722–736. doi: 10.1194/jlr.P056002. PubMed DOI PMC

Mayo R., Crespo J., Martínez-Arranz I., Banales J.M., Arias M., Mincholé I., Aller de la Fuente R., Jimenez-Agüero R., Alonso C., de Luis D.A., et al. Metabolomic-based Noninvasive Serum Test to Diagnose Nonalcoholic Steatohepatitis: Results from Discovery and Validation Cohorts. Hepatol. Commun. 2018;2:807–820. doi: 10.1002/hep4.1188. PubMed DOI PMC

Mato J., Alonso C., Noureddin M., Lu S. Biomarkers and Subtypes of Deranged Lipid Metabolism in Non-Alcoholic Fatty Liver Disease. World J. Gastroenterol. 2019;25:3009–3020. doi: 10.3748/wjg.v25.i24.3009. PubMed DOI PMC

Gorden D.L., Ivanova P.T., Myers D.S., McIntyre J.O., VanSaun M.N., Wright J.K., Matrisian L.M., Brown H.A. Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model. PLoS ONE. 2011;6:e22775. doi: 10.1371/journal.pone.0022775. PubMed DOI PMC

Ma D.W.L., Arendt B.M., Hillyer L.M., Fung S.K., McGilvray I., Guindi M., Allard J.P. Plasma Phospholipids and Fatty Acid Composition Differ between Liver Biopsy-Proven Nonalcoholic Fatty Liver Disease and Healthy Subjects. Nutr. Diabetes. 2016;6:e220. doi: 10.1038/nutd.2016.27. PubMed DOI PMC

Anjani K., Lhomme M., Sokolovska N., Poitou C., Aron-Wisnewsky J., Bouillot J.-L., Lesnik P., Bedossa P., Kontush A., Clement K., et al. Circulating Phospholipid Profiling Identifies Portal Contribution to NASH Signature in Obesity. J. Hepatol. 2015;62:905–912. doi: 10.1016/j.jhep.2014.11.002. PubMed DOI

Birerdinc A., Younossi Z. Can NASH Lipidome Provide Insight into the Pathogenesis of Obesity-Related Non-Alcoholic Fatty Liver Disease? J. Hepatol. 2015;62 doi: 10.1016/j.jhep.2015.01.005. PubMed DOI

Montefusco D.J., Allegood J.C., Spiegel S., Cowart L.A. Non-Alcoholic Fatty Liver Disease: Insights from Sphingolipidomics. Biochem. Biophys. Res. Commun. 2018;504:608–616. doi: 10.1016/j.bbrc.2018.05.078. PubMed DOI PMC

Nikolova-Karakashian M. Sphingolipids at the Crossroads of NAFLD and Senescence. Adv. Cancer Res. 2018;140:155–190. doi: 10.1016/bs.acr.2018.05.002. PubMed DOI

Bony S., Carcelen M., Olivier L., Devaux A. Genotoxicity Assessment of Deoxynivalenol in the Caco-2 Cell Line Model Using the Comet Assay. Toxicol. Lett. 2006;166:67–76. doi: 10.1016/j.toxlet.2006.04.010. PubMed DOI

Da Silva E.O., Bracarense A.P., Oswald I.P. Mycotoxins and Oxidative Stress: Where Are We? World Mycotoxin J. 2018;11:113–134. doi: 10.3920/WMJ2017.2267. DOI

Wu Q.-H., Wang X., Yang W., Nüssler A.K., Xiong L.-Y., Kuča K., Dohnal V., Zhang X.-J., Yuan Z.-H. Oxidative Stress-Mediated Cytotoxicity and Metabolism of T-2 Toxin and Deoxynivalenol in Animals and Humans: An Update. Arch. Toxicol. 2014;88:1309–1326. doi: 10.1007/s00204-014-1280-0. PubMed DOI

Ferrer E., Juan-García A., Font G., Ruiz M.J. Reactive Oxygen Species Induced by Beauvericin, Patulin and Zearalenone in CHO-K1 Cells. Toxicol. Vitro. 2009;23:1504–1509. doi: 10.1016/j.tiv.2009.07.009. PubMed DOI